SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae

D. Szabó, Robert A. Bonomo, Fernanda Silveira, A. William Pasculle, Carla Baxter, Peter K. Linden, Andrea M. Hujer, Kristine M. Hujer, Kathleen Deeley, David L. Paterson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Cefepime is a potentially useful antibiotic for treatment of infections with Enterobacter cloacae. However, in our institution the MIC90 for E. cloacae bloodstream isolates is 16 μg/ml. PCR amplification of bla genes revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to hyperproduction of AmpC-type beta-lactamases. The majority (11/15) of ESBL producers also produced the TEM-1 beta-lactamase. The SHV types included SHV-2, -5, -7, -12, -14, and -30. All but two of the ESBL-producing E. cloacae isolates, but none of the non-ESBL-producing strains, had MICs of cefepime of ≥2 μg/ml. The MIC90 for cefepime for ESBL-producing strains was 64 μg/ml, while for non-ESBL producers it was 0.5 μg/ml. Using current Clinical and Laboratory Standards Institute breakpoints for cefepime, two thirds (10/15) of ESBL-producing isolates would have been regarded as susceptible to cefepime. Phenotypic ESBL detection methods were generally unreliable with these E. cloacae isolates. Based on these results, pharmacokinetic, pharmacodynamic, and clinical reevaluation of cefepime breakpoints for E. cloacae may be prudent.

Original languageEnglish
Pages (from-to)5058-5064
Number of pages7
JournalJournal of Clinical Microbiology
Volume43
Issue number10
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Enterobacter cloacae
beta-Lactamases
cefepime
Gene Amplification
Pharmacokinetics
Anti-Bacterial Agents
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. / Szabó, D.; Bonomo, Robert A.; Silveira, Fernanda; Pasculle, A. William; Baxter, Carla; Linden, Peter K.; Hujer, Andrea M.; Hujer, Kristine M.; Deeley, Kathleen; Paterson, David L.

In: Journal of Clinical Microbiology, Vol. 43, No. 10, 10.2005, p. 5058-5064.

Research output: Contribution to journalArticle

Szabó, D, Bonomo, RA, Silveira, F, Pasculle, AW, Baxter, C, Linden, PK, Hujer, AM, Hujer, KM, Deeley, K & Paterson, DL 2005, 'SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae', Journal of Clinical Microbiology, vol. 43, no. 10, pp. 5058-5064. https://doi.org/10.1128/JCM.43.10.5058-5064.2005
Szabó, D. ; Bonomo, Robert A. ; Silveira, Fernanda ; Pasculle, A. William ; Baxter, Carla ; Linden, Peter K. ; Hujer, Andrea M. ; Hujer, Kristine M. ; Deeley, Kathleen ; Paterson, David L. / SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. In: Journal of Clinical Microbiology. 2005 ; Vol. 43, No. 10. pp. 5058-5064.
@article{d688ca52f017462fbf5fd141bdd55ccc,
title = "SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae",
abstract = "Cefepime is a potentially useful antibiotic for treatment of infections with Enterobacter cloacae. However, in our institution the MIC90 for E. cloacae bloodstream isolates is 16 μg/ml. PCR amplification of bla genes revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to hyperproduction of AmpC-type beta-lactamases. The majority (11/15) of ESBL producers also produced the TEM-1 beta-lactamase. The SHV types included SHV-2, -5, -7, -12, -14, and -30. All but two of the ESBL-producing E. cloacae isolates, but none of the non-ESBL-producing strains, had MICs of cefepime of ≥2 μg/ml. The MIC90 for cefepime for ESBL-producing strains was 64 μg/ml, while for non-ESBL producers it was 0.5 μg/ml. Using current Clinical and Laboratory Standards Institute breakpoints for cefepime, two thirds (10/15) of ESBL-producing isolates would have been regarded as susceptible to cefepime. Phenotypic ESBL detection methods were generally unreliable with these E. cloacae isolates. Based on these results, pharmacokinetic, pharmacodynamic, and clinical reevaluation of cefepime breakpoints for E. cloacae may be prudent.",
author = "D. Szab{\'o} and Bonomo, {Robert A.} and Fernanda Silveira and Pasculle, {A. William} and Carla Baxter and Linden, {Peter K.} and Hujer, {Andrea M.} and Hujer, {Kristine M.} and Kathleen Deeley and Paterson, {David L.}",
year = "2005",
month = "10",
doi = "10.1128/JCM.43.10.5058-5064.2005",
language = "English",
volume = "43",
pages = "5058--5064",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae

AU - Szabó, D.

AU - Bonomo, Robert A.

AU - Silveira, Fernanda

AU - Pasculle, A. William

AU - Baxter, Carla

AU - Linden, Peter K.

AU - Hujer, Andrea M.

AU - Hujer, Kristine M.

AU - Deeley, Kathleen

AU - Paterson, David L.

PY - 2005/10

Y1 - 2005/10

N2 - Cefepime is a potentially useful antibiotic for treatment of infections with Enterobacter cloacae. However, in our institution the MIC90 for E. cloacae bloodstream isolates is 16 μg/ml. PCR amplification of bla genes revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to hyperproduction of AmpC-type beta-lactamases. The majority (11/15) of ESBL producers also produced the TEM-1 beta-lactamase. The SHV types included SHV-2, -5, -7, -12, -14, and -30. All but two of the ESBL-producing E. cloacae isolates, but none of the non-ESBL-producing strains, had MICs of cefepime of ≥2 μg/ml. The MIC90 for cefepime for ESBL-producing strains was 64 μg/ml, while for non-ESBL producers it was 0.5 μg/ml. Using current Clinical and Laboratory Standards Institute breakpoints for cefepime, two thirds (10/15) of ESBL-producing isolates would have been regarded as susceptible to cefepime. Phenotypic ESBL detection methods were generally unreliable with these E. cloacae isolates. Based on these results, pharmacokinetic, pharmacodynamic, and clinical reevaluation of cefepime breakpoints for E. cloacae may be prudent.

AB - Cefepime is a potentially useful antibiotic for treatment of infections with Enterobacter cloacae. However, in our institution the MIC90 for E. cloacae bloodstream isolates is 16 μg/ml. PCR amplification of bla genes revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to hyperproduction of AmpC-type beta-lactamases. The majority (11/15) of ESBL producers also produced the TEM-1 beta-lactamase. The SHV types included SHV-2, -5, -7, -12, -14, and -30. All but two of the ESBL-producing E. cloacae isolates, but none of the non-ESBL-producing strains, had MICs of cefepime of ≥2 μg/ml. The MIC90 for cefepime for ESBL-producing strains was 64 μg/ml, while for non-ESBL producers it was 0.5 μg/ml. Using current Clinical and Laboratory Standards Institute breakpoints for cefepime, two thirds (10/15) of ESBL-producing isolates would have been regarded as susceptible to cefepime. Phenotypic ESBL detection methods were generally unreliable with these E. cloacae isolates. Based on these results, pharmacokinetic, pharmacodynamic, and clinical reevaluation of cefepime breakpoints for E. cloacae may be prudent.

UR - http://www.scopus.com/inward/record.url?scp=26944470372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944470372&partnerID=8YFLogxK

U2 - 10.1128/JCM.43.10.5058-5064.2005

DO - 10.1128/JCM.43.10.5058-5064.2005

M3 - Article

VL - 43

SP - 5058

EP - 5064

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 10

ER -